Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending December 31, 2022
February 09, 2022 at 11:30 pm EST
Share
Otsuka Holdings Co., Ltd. provided consolidated earnings guidance for the second quarter and full year of fiscal ending December 31, 2022. For the period, the company expected revenue of JPY 767,000 million, operating profit of JPY 112,500 million, profit for the period of JPY 87,500 million and basic earnings per share of JPY 158.55.
For the fiscal year, the company expected revenue of JPY 1,550,000 million, operating profit of JPY 192,000 million, profit for the period of JPY 149,000 million and basic earnings per share of JPY 269.17.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
